Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society. The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.

Disclaimer
This information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.

Learning Objectives
Upon completion of this educational activity, learners will be able to:

• Explain the rationale for and implications of proposed changes to diagnostic criteria for T2DM
• Recognize patient barriers to medication adherence
• Recognize the adverse outcomes associated with hypoglycemia and ways to prevent hypoglycemic events with particular attention to matching the anti-hyperglycemia regimen
  to nutritional intake
• Define medically significant weight loss and its impact on glycemic parameters
• Effectively describe the appropriate use of incretin mimetics and DPP-4 inhibitors in
  diabetes treatment
• Select appropriate medical therapy options for obesity
• Correctly apply new diabetes screening and diagnostic recommendations
• Choose the best therapeutic options for managing dyslipidemia in patients with T2DM
• Identify blood pressure treatment targets and preferred pharmacologic treatment options
  for patients with diabetes
• Appropriately manage insulin therapy in the hospitalized patient
• Recognize the causes and risks of recurrent hypoglycemia and hypoglycemia unawareness

Target Audience
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, pediatric endocrinologists, pediatric endocrine fellows, endocrine physician assistants, internal medicine physicians, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

Disclosure Policy
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting frees; salary; ownership interest
(e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureau, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Louis J. Aronne, MD, has received research support from Amylin Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd, Merck & Co., Inc., Novo Nordisk, Orexigen Therapeutics, Inc., Pfizer Inc., TransTech Pharma, Inc., Schering-Plough (Merck), VIVUS Inc., sanofi-aventis U.S.; is a scientific advisor to Amylin Pharmaceuticals, Inc., GI Dynamics, F. Hoffman La-Roche Ltd, Johnson & Johnson, NeuroSearch, Novo Nordisk, Orexigen Therapeutics, Inc.; has ownership interest in Cardiometabolic Support Network
Silva A. Arslanian, MD, has received consulting fees from VeroScience, F. Hoffman La-Roche Ltd, Medtronic, Inc. (spouse), sanofi-aventis U.S., Novo Nordisk, and MetaCure Inc.; has received honoraria for her role as a speaker from Eli Lilly and Company
Irl B. Hirsch, MD, has received research grant support from Novo Nordisk and MannKind Corporation; has received consulting fees from Johnson & Johnson, F. Hoffman La-Roche Ltd, and Bayer HealthCare Pharmaceuticals, Inc.
Anthony L. McCall, MD, has received honoraria for his role as a speaker from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company; has received research support from sanofi-aventis U.S.
Kwame Osei, MD, has received consulting fees for his role as advisory board member from Eli Lilly and Company and Daiichi Sankyo Co., Ltd.; has received speaker honoraria from Novo Nordisk.
Robert E. Ratner, MD, has received consulting fees from his role as advisory board member from Amylin Pharmaceuticals, Inc

Julio Rosenstock, MD, has received research grant support from Merck & Co., Inc., Pfizer Inc., sanofi-aventis U.S., Novo Nordisk, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Novartis, AstraZeneca, Amylin Pharmaceuticals, Inc., Johnson & Johnson, Daiichi Sankyo Co., Ltd., and MannKind Corporation; has received consulting fees for his role as advisory committee member from Pfizer Inc., F. Hoffman La-Roche Ltd, sanofi-aventis U.S., Novo Nordisk, Eli Lilly and Company, MannKind Corporation, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd., Centocor Ortho Biotech Inc., Johnson & Johnson, Emisphere Technologies, Inc., Novartis, and Amylin Pharmaceuticals, Inc.

The following faculty reported no relevant financial relationships: Sharon Anderson, MD; Robert M. Cuddihy, MD; Arshag D. Mooradian, MD; David M. Nathan, MD; Elizabeth R. Seaquist, MD; Lisa R. Tannock, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
Medtelligence, LLC staff associated with the development of content for this activity reported no relevant financial relationships.

Policy on Unlabeled/Off-Label Use
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.

Use of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Privacy & Confidentiality Statement

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Acknowledgement of Commercial Support
This activity is supported by educational grants from Amylin Pharmaceuticals, Inc. and Lilly USA, LLC; Bristol-Myers Squibb and AstraZeneca; Genentech, Inc.; Merck & Co., Inc.; Novo Nordisk; and sanofi-aventis U.S.

METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:

• For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed.
• For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.

To receive AMA PRA Category 1 Credits™, the learner should:

• Listen to the audio and/or view the slides.
  
• Complete the evaluation provided at the end of the activity and click on "submit" to add it to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing other CME offerings.
• Estimated time to complete this activity: 4.50 hours

Last Review Date: June 30, 2010

RELEASE DATE: June 30, 2010
TERMINATION DATE: June 30, 2011

For technical assistance or information, please contact Content Management Corporation at 1-888-711-1138 ext.241 or 972-910-6899 (9:00 AM to 5:00 PM EST or multiviewMediaSupport@multiview.com.
For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or vparcan@endo-society.org.